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Background: Gastric endoscopic submucosal dissection (ESD) has gradually come to be recommended as the
optimal treatment for early gastric cancer; however, one of the primary issues is postoperative bleeding. Although
second-look endoscopy is conventionally performed to reduce the risk of postoperative bleeding, its benefit has
not yet been clearly elucidated. The objective of this study was to elucidate the benefit of second-look endoscopy.
Methods: A total of 459 lesions in patients were underwent gastric ESD from May 2004 to April 2013 at our
hospital were included in the analysis. The patients were divided into those who had bleeding within 24 hours
after ESD (immediate bleeding) and those in whom bleeding occurred 24 hours or more after the procedure
(delayed bleeding); the underlying disease, age, lesion site, diameter of the resected specimen, and lesion diameter
were analyzed to identify the risk factors for postoperative bleeding after ESD.
Results: Post-ESD immediate or delayed bleeding occurred in 23 of the 459 cases (5.0%). Second-look endoscopy
was performed in 210 of 447 cases (47.0%) excluding 12 cases with immediate bleeding; in the remaining 237 of
the 447 cases (53.0%), it was not performed. Post-ESD delayed bleeding occurred in 6 of the 210 cases (2.9%) and
5 of the 237 cases (2.1%), with no statistically significant difference between the two groups. Overall, the following
factors were identified as the risk factors for postoperative bleeding: young age (P = 0.005), lesions in the L segment
(P = 0.042), and large size of the resected specimen (P = 0.005). The risk factors identified in the immediate bleeding
group were lesions in the L segment (P = 0.032), large size of the resected specimen (P < 0.001), and large tumor
size (P = 0.011), and those in the delayed bleeding group were young age (P = 0.013) and concomitant renal disease
(P = 0.011).
Conclusions: The results of this study suggest that second-look endoscopy after gastric ESD may not be useful for
preventing postoperative bleeding.
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Gastric ESD has gradually come to be recommended as
the optimal treatment for early gastric cancer. This tech-
nique can now be used for the resection of large lesions
and ulcer lesions which cannot be resected by traditional
endoscopic mucosal resection [1–3].
Postoperative bleeding is one among the major compli-
cations of ESD. According to past reports, post-ESD* Correspondence: naoto-y@dokkyomed.ac.jp
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[4–6]. While the frequency of postoperative bleeding is
gradually decreasing owing to the development of post-
ESD coagulation therapy and use of proton pump inhibi-
tors (PPI), it remains one of the primary issues that need
to be resolved in relation to ESD. Second-look endoscopy
after hemostasis for peptic ulcer bleeding has been re-
ported to be useful for the prevention of rebleeding [7–9].
Therefore, second-look endoscopy is also conventionally
performed post-ESD at many institutions; however, its
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whether second-look endoscopy might be useful for the
prevention of post-ESD bleeding. We also evaluated the
risk factors for postoperative bleeding.
Methods
Patients and lesions
We targeted a total of 488 lesions in patients who
underwent gastric ESD between May 2004 and April
2013 at our hospital. In cases with multiple synchronous
lesions, those lesions that showed deeper invasion or
were larger in diameter if the invasion depth was the
same were included. After exclusion of a total of 29 le-
sions (11 with a residual cancer lesion, 12 with perfor-
ation, 2 with aspiration pneumonitis, 1 in which the
treatment was switched to open surgery, and 3 in which
no evidence of cancer was found in the resected speci-
men), a total of 459 lesions (405 lesions of early gastric
cancer, 54 lesions of gastric adenoma) were considered
to be evaluable. Table 1 shows the clinicopathological
characteristics of these patients.
Prior to the ESD, the patients had undergone endo-
scopic examinations, including chromoendoscopy, mag-Table 1 Clinicopathological features of patients and
gastric lesions
Age (year, mean ± SD) 71.4 ± 8.8
Gender Man/Woman 344 (74.9%)/115 (25.1%)
Lesion
Elevated type/Depressed type 256 (55.8%)/203 (44.2%)
Tumor location U/M/L 75 (16.3%)/179 (39.0%)/205
(44.7%)
Size of resected specimen
(mm, mean ± SD)
40.3 ± 15.3




Depth of invasion (M/SM1/SM2) 405 (88.2%)/39 (8.5%)/15 (3.3%)
Ulcerative findings absent/present 426 (92.8%)/33 (7.2%)
Resectability
One-piece resection 446 (97.2%)
Complete resection 403 (87.8%)
Underlying diseases
Heart disease 72 (15.7%)
Renal disease 21 (4.6%)
Hepatic disease 45 (9.8%)
Pulmonary disease 36 (7.8%)
Brain disease 45 (9.8%)
Hypertension 209 (45.5%)
Diabetes mellitus 75 (16.3%)
Hyperlipidemia 67 (14.6%)nified endoscopy, endoscopic ultrasonography, and biopsy,
and thoracoabdominal computed tomography. Gastric
ESD was indicated for early gastric cancers satisfying the
criteria of Gotoda et al., lesions that were strongly sus-
pected as being cancerous, and adenomas for which pa-
tients requested resection [10,11].
This study protocol was approved by Dokkyo Medical
University Ethics Committee. All patients gave written
informed consent before the procedure.
ESD procedure and management
Patients orally received rabeprazole sodium 20 mg/day
from the day prior to ESD to increase the gastric pH and
achieve easy hemostasis at the time of ESD [12,13].
At the time of the ESD procedure, the patients re-
ceived pentazocine 15 mg/dose/h and continuous propo-
fol intravenous infusion for sedation. Propofol was
administered in accordance with the method described
in the paper of Kiriyama et al. [14] The ESD procedure
is described elsewhere [15–17]. In short, the peripheries
of lesions were marked using the Dual Knife (KD-650 L;
Olympus). A local injection solution was prepared by
mixing glycerol and sodium hyaluronate at a 1:1 ratio
and adding adrenaline and indigo carmine. The solution
was locally injected into the submucosal layer [18,19].
Next, the lesion was circumferentially incised with a
margin of 5 mm outside the marking using Dual Knife
or IT Knife (KD-610 L, Olympus), followed by the
resection of the submucosal layer below the lesion, just
above the muscle layer. If there was a little bleeding,
hemostasis was achieved with the knife used during the
ESD procedure. However, in the event of moderate to
severe bleeding, hemostasis was achieved using Coagras-
per (FD-411QR, Olympus). In most cases, the bleeding
could be stopped with hemostatic forceps; however, in
rare cases in which the bleeding could not be stopped,
the EZ Clip (HX-610-135, Olympus) was used. Immedi-
ately after the ESD, the exposed blood vessels at the base
of the ulcer were treated with hemostatic forceps or a
clip, to the extent possible [19,20].
In general, the patients underwent blood tests and thor-
acoabdominal radiography on the day after the ESD; if
there were no problems, they were allowed to take fluids;
from day 2 after ESD, they were allowed to take meals
orally, starting with rice gruel. In case second-look endos-
copy was performed, it was performed within a few days
after the ESD (1.24 ± 0.53 days, range 1–3 days). When
the second-look endoscopy revealed hemorrhage or
exposed vessels, hemostasis was performed using the
hemostatic forceps or a clip. When perforation or post-
ESD bleeding was observed, the schedule of discharge and
meal resumption was changed depending on the individ-
ual patients’ condition. If post-ESD bleeding occurred,
emergency endoscopy was performed, and endoscopic
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the patients had no problems during the course of
hospitalization, they were discharged within 1 week after
the ESD.
During the interval period from the ESD to resumption
of oral meal intake (usually 2 days), the patients were
managed by twice-daily intravenous administration of
20 mg omeprazole or 30 mg lansoprazole. After oral in-
take of meals was resumed, the patients were given oral
rabeprazole sodium 20 mg/day for 8 weeks [21].
If the patients were receiving oral anticoagulant or anti-
platelet drugs, these drugs were suspended in accordance
with the Gastroenterological Endoscopy Guidelines, Ver-
sion 3 [22]. The drug administrations were resumed from
day 2 after the ESD, i.e., at the same time as the resump-
tion of oral meal intake.
Patients were instructed to visit the hospital immedi-
ately if they noticed hematemesis or melena after dis-
charge from the hospital.
Data analysis
Post-ESD bleeding was defined as postoperative hematem-
esis or melena requiring endoscopic hemostasis. Post-ESD
bleeding diagnosed within 24 hours after the ESD wasTable 2 Comparison of characteristics between second-look e
SLE group (n = 210)
Age (year, mean ± SD) 71.5 ± 8.3






Elevated type/Depressed type 115 (54.8%)/95 (45.2%)
Tumor size
(mm, mean ± SD) 16.5 ± 9.0
Histopathology
Adenoma/Carcinoma 30 (14.3%)/180 (85.7%)
Depth of invasion
M/SM 189 (90.0%)/21 (10.0%)
Heart disease 35 (16.7%)
Renal disease 7 (3.3%)
Hepatic disease 23 (11.0%)
Pulmonary disease 13 (6.2%)
Brain disease 24 (11.4%)
Hypertension 92 (43.8%)
Diabetes mellitus 36 (17.1%)
Hyperlipidemia 23 (11.0%)defined as immediate bleeding, while bleeding diagnosed
later than that was referred to as delayed bleeding. In
order to evaluate the benefit of second-look endoscopy,
the frequency of delayed bleeding was examined between
patients who underwent/did not undergo second-look
endoscopy.
The following factors were analyzed to identify the risk
factors for post-ESD bleeding: age, sex, lesion site (upper,
middle, lower stomach), lesion form (raised, depressed),
size of the resected specimen, lesion size, pathological
findings (adenoma, carcinoma), whether an ulcer was
formed/not formed, whether en bloc resection was pos-
sible or not, the underlying diseases (hypertension, renal,
cardiac, pulmonary or brain disease, diabetes, dyslipid-
emia), and the status of treatment with antiplatelet and
anticoagulant agents (yes/no).
Statistical analysis
Univariate analysis was performed on each item. The age
and sizes of the resected specimen and lesion were
analyzed by Student’s t-test. Chi-square analysis was
performed on other data, while Fisher’s exact test was
used for the items with an expected value of 5 or more. A
P < 0.05 was determined as statistically significant.ndoscopy group and non-endoscopy group
Non-SLE group (n = 237) P value
71.6 ± 9.2 0.892 (NS)
172 (72.6%)/65 (27.4%) 0.263 (NS)
45 (19.0%) 0.315 (NS)
97 (40.9%) 0.537 (NS)
95 (40.1%) 0.108 (NS)
132 (55.7%)/105 (44.3%) 0.918 (NS)
17.5 ± 11.8 0.309 (NS)
41 (17.3%)/196 (82.7%) 0.460 (NS)
223 (94.1%)/14 (5.9%) 0.152 (NS)
34 (14.3%) 0.584 (NS)
14 (5.9%) 0.289 (NS)
19 (8.0%) 0.368 (NS)
20 (8.4%) 0.661 (NS)
18 (7.6%) 0.221 (NS)
121 (51.1%) 0.126 (NS)
38 (6.0%) 0.851 (NS)
41 (17.3%) 0.056 (NS)
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Post-ESD bleeding was observed in 23 of the 459 cases
(5.0%). Immediate bleeding and delayed bleeding were ob-
served in 12 (52.2%) and 11 cases (47.8%), respectively.
Bleeding could be stopped in all patients by endoscopic
treatment, and none of the patients required surgical
treatment. Postoperative bleeding occurred 8 days or later
in 3 patients, and all of them were on treatment with anti-
platelet agents.
Second-look endoscopy was performed in 210 of 447
patients (47.0%) excluding 12 cases with immediate bleed-
ing; and the remaining 237 patients (53.0%) did not
undergo second-look endoscopy. No statistically signifi-
cant differences were observed between the groups that
underwent/did not undergo second-look endoscopy in the
age, gender ratio, tumor location, macroscopic type,
tumor size, histopathology, depth of invasion, or patients’
medical history (Table 2). Postoperative bleeding was ob-
served in 6 of the 210 patients (2.9%) in the endoscopy
group and 5 of the 237 patients (2.1%) in the non-
endoscopy group, the difference not being statistically
significant; i.e., the postoperative bleeding rates were com-
parable in the two groups (Figure 1).
The risk factors for post-ESD bleeding were evaluated, in-
cluding the patients’ medical history. Overall, the risk fac-
tors for postoperative bleeding were younger age (66.4 ±
11.3 vs. 71.7 ± 8.6 years, P = 0.005), lesions in the L segmentFigure 1 Flowchart showing the analysis of the usefulness of second-(L vs. UM, P = 0.042), and large resected specimens (49.1 ±
25.8 vs. 39.9 ± 14.4 mm, P = 0.005) (Table 3). Analysis of
the immediate bleeding subgroup revealed that postopera-
tive bleeding occurred more frequently in cases with lesion
in the L segment (L vs. UM, P = 0.032), large resected speci-
men (58.3 ± 29.5 vs. 39.9 ± 14.4 mm, P < 0.001), and large
tumor size (25.3 ± 19.9 vs. 17.0 ± 10.6 mm, P = 0.011)
(Table 4). On the other hand, evaluation of the risk factors
in the delayed bleeding subgroup revealed younger age
(64.9 ± 12.7 vs. 71.6 ± 8.6 years, P = 0.013) and concomitant
renal disease (P = 0.011) as the risk factors (Table 5).
Discussion
Several studies have reported the usefulness of second-
look endoscopy following endoscopic hemostasis to pre-
vent bleeding in patients with hemorrhagic peptic ulcer
[7–9]. Based on such studies, second-look endoscopy
has come to be conventionally performed after ESD as
well. Recently, we found reports, albeit only a few, of the
benefit of second-look endoscopy following ESD. Kim
et al. support the performance of second-look endoscopy
following ESD [23], whereas Goto et al. and Ryu et al.
reported that second-look endoscopy was not effective
for preventing post-ESD bleeding [24,25]. In our study,
no difference was observed in the postoperative bleeding
rate between the groups that did and did not undergo
second-look endoscopy. Consistent with the reports oflook endoscopy to prevent the bleeding after ESD.
Table 3 Analysis of risk factors related to post-ESD bleeding
Bleeding group (n = 23) Non-bleeding group (n = 237) P value
Age (year, mean ± SD) 66.4 ± 11.3 71.7 ± 8.6 0.005
Gender Man/Woman 16 (69.6%)/7 (30.4%) 328 (75.2%)/108 (24.8%) 0.715 (NS)
Tumor location
U 1 (4.3%) 74 (17.0%) 0.149 (NS)
M 7 (30.4%) 172 (39.4%) 0.519 (NS)
L 15 (65.2%) 190 (43.6%) 0.042
Macroscopic type
Elevated type/Depressed type 16 (69.6%)/7 (30.4%) 240 (54.9%)/196 (55.0%) 0.250 (NS)
Size of resected specimen
(mm, mean ± SD) 49.1 ± 25.8 39.9 ± 14.4 0.005
Tumor size
(mm, mean ± SD) 21.1 ± 17.2 17.0 ± 10.6 0.087 (NS)
Histopathology
Adenoma/Carcinoma 3 (13.0%)/20 (87.0%) 49 (11.2%)/387 (88.8%) 0.736 (NS)
Depth of invasion
M/SM 21 (91.3%)/2 (8.7%) 384 (88.1%)/52 (11.9%) >0.999 (NS)
Ulcerative findings
None/present 22 (95.7%)/1 (4.3%) 405 (92.9%)/31 (7.1%) >0.999 (NS)
Resected style
One-piece/Piecemeal 21 (91.3%)/2 (8.7%) 382 (87.6%)/54 (12.4%) >0.999 (NS)
Heart disease 4 (17.4%) 68 (15.6%) 0.770 (NS)
Renal disease 3 (13.0%) 18 (4.1%) 0.081 (NS)
Hepatic disease 4 (17.4%) 41 (9.4%) 0.267 (NS)
Pulmonary disease 4 (17.4%) 32 (7.3%) 0.096 (NS)
Brain disease 3 (13.0%) 42 (9.6%) 0.484 (NS)
Hypertension 12 (52.2%) 197 (45.2%) 0.659 (NS)
Diabetes mellitus 4 (17.4%) 71 (16.3%) 0.778 (NS)
Hyperlipidemia 4 (17.4%) 63 (14.4%) 0.760 (NS)
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second-look endoscopy following ESD did not reduce
the risk of postoperative bleeding. One of the possible
reasons is the effect of the gastric pH. Control of bleed-
ing is known to be difficult in the presence of a low
gastric pH [13,26]. As the gastric pH is low in patients
undergoing endoscopic treatment for peptic ulcer, re-
bleeding is prone to occur in these patients, and second-
look endoscopy is considered to be useful. In contrast,
the gastric pH is high at the time of ESD due to the PPI
therapy initiated from the previous day, and the risk of
rebleeding is lower; therefore, second-look endoscopy
may not be required. As the base of a peptic ulcer in the
active phase is often covered with a white moss, it is dif-
ficult to visually recognize the narrow blood vessels,
though thick blood vessels can be visually recognized.
Therefore, it is difficult to treat narrow vessels. On the
other hand, no white moss is observed in ulcers at theend of the ESD and the narrow vessels can be more
clearly recognized, and, therefore, can also be treated. It
has been reported that treatment of the visualized blood
vessels using hemostatic forceps or a clip at the end of
ESD is very useful for reducing post-ESD bleeding
[19,20]. Furthermore, Tsuji et al. reported that postoper-
ative bleeding is more common at the margin than at
the center of the ulcer base [27]. At our hospital, we
treat the visible blood vessels focusing on the ulcer mar-
gin in all patients at the end of ESD. As it is possible to
treat more blood vessels at the end of ESD than at the
time of endoscopic treatment of peptic ulcers, perform-
ance of second-look endoscopy following ESD may not
have any influence on the incidence of postoperative
bleeding.
There are many reports of the risk factors for post-ESD
bleeding, including flat or depressed-type lesions, lesions
in the L segment, large resected specimens, long operative
Table 4 Analysis of risk factors related to immediate bleeding after ESD
Immediate bleeding group (n = 12) Non-immediate bleeding group (n = 447) P value
Age (year, mean ± SD) 67.8 ± 9.7 71.5 ± 8.8 0.142 (NS)
Gender Man/Woman 8 (66.7%)/4 (33.3%) 335 (74.9%)/108 (25.1%) 0.710 (NS)
Tumor location
U 0 (0%) 75 (16.8%) 0.230 (NS)
M 3 (25.0%) 176 (39.4%) 0.382 (NS)
L 9 (75.0%) 196 (43.8%) 0.032
Macroscopic type
Elevated type/Depressed type 9 (75.0%)/3 (25.0%) 251 (54.9%)/196 (46.3%) 0.246 (NS)
Size of resected specimen
(mm, mean ± SD) 58.3 ± 29.5 39.9 ± 14.4 0.005
Tumor size
(mm, mean ± SD) 25.3 ± 19.9 17.0 ± 10.6 0.011
Histopathology
Adenoma/Carcinoma 2 (16.7%)/10 (83.3%) 71 (15.9%)/376 (84.1%) >0.999 (NS)
Depth of invasion
M/SM 11 (91.7%)/1 (8.3%) 412 (92.2%)/35 (7.8%) >0.999 (NS)
Ulcerative findings
None/present 12 (100%)/0 (0.0%) 414 (92.6%)/33 (7.4%) >0.999 (NS)
Resected style
One-piece/Piecemeal 12 (100%)/0 (0%) 434 (97.1%)/13 (2.9%) >0.999 (NS)
Heart disease 3 (25.0%) 69 (15.4%) 0.413 (NS)
Renal disease 0 (0.0%) 21 (4.7%) >0.999 (NS)
Hepatic disease 3 (25.0%) 42 (9.4%) 0.103 (NS)
Pulmonary disease 3 (25.0%) 33 (7.4%) 0.060 (NS)
Brain disease 3 (25.0%) 42 (9.4%) 0.103 (NS)
Hypertension 6 (50.0%) 203 (45.4%) 0.983 (NS)
Diabetes mellitus 1 (8.3%) 74 (16.6%) 0.700 (NS)
Hyperlipidemia 3 (25.0%) 64 (14.3%) 0.396 (NS)
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lysis, and oral intake of antiplatelet agents [5,24,28,29].
Among these, lesions in the L segment and large resected
specimens have been reported from multiple researches.
In our study, postoperative bleeding was more common
in patients with a large resected specimen, lesion in the L
segment, and young patients. As bleeding within 24 hours
of the ESD procedure accounts for approximately half of
all cases of postoperative bleeding, the risk factors for
bleeding within 24 hours of ESD (immediate bleeding)
and those for bleeding occurring later (delayed bleeding)
were investigated. This is the first report of investigation
of patients with post-ESD bleeding in detail over time. In
this study, immediate bleeding occurred significantly more
frequently in patients with lesions in the L segment, large
resected specimens, and large tumor size. On the other
hand, delayed bleeding was significantly more common in
younger patients and patients with concomitant renaldisease. In other words, lesion factors predominantly af-
fected the bleeding risk in the early stage after the ESD
and patient factors predominantly affected the bleeding
risk in the later stages after the procedure. In the case of
large resected specimens, multiple blood vessels are
present in the ulcer base, according to their size, increas-
ing the risk of bleeding. Okada et al. reported that the vol-
ume of postoperative bleeding was 8.2-fold higher when
the resected specimen was larger than 4 cm in diameter
[29]. It has been shown that the number and diameter of
submucosal arteries in the L segment are less and smaller,
respectively, than those in the other gastric segments [30],
suggesting that lesions in the L segment of the stomach
may be associated with less intraoperative bleeding and
therefore less hemostatic intervention. As lesions in the L
segment are prone to bile exposure which refluxes into
the stomach, and a large amount of local injection solu-
tion enters the submucosal layer in this segment, blood
Table 5 Anaysis of risk factors related to delayed bleeding after ESD
Delayed bleeding group (n = 11) Non-delayed bleeding group (n = 448) P value
Age (year.mean ± SD) 64.9 ± 12.7 71.6 ± 8.6 0.013
Gender Man/Woman 8 (72.7%)/3 (27.3%) 336 (75.0%)/112 (25.0%) >0.999 (NS)
Tumor location
U 1 (9.1%) 74 (16.5%) >0.999 (NS)
M 4 (36.4%) 175 (39.1%) >0.999 (NS)
L 6 (54.5%) 199 (44.4%) 0.551 (NS)
Macroscopic type
Elevated type/Depressed type 7 (63.6%)/4 (36.4%) 249 (55.6%)/199 (44.4%) 0.762 (NS)
Size of resected specimen
(mm, mean ± SD) 39.2 ± 16.1 40.4 ± 15.3 0.800 (NS)
Tumor size
(mm, mean ± SD) 16.5 ± 12.2 17.3 ± 11.0 0.832 (NS)
Histopathology
Adenoma/Carcinoma 2 (18.2%)/9 (81.8%) 71 (15.8%)/377 (84.2%) 0.690 (NS)
Depth of invasion
M/SM 11 (100%)/0 (0.0%) 412 (92.0%)/36 (8.0%) >0.999 (NS)
Ulcerative findings
None/present 9 (81.8%)/2 (18.2%) 417 (93.1%)/31 (6.9%) 0.184 (NS)
Resected style
One-piece/Piecemeal 11 (100%)/0 (0%) 435 (97.1%)/13 (2.9%) >0.999 (NS)
Heart disease 1 (9.1%) 71 (15.8%) >0.999 (NS)
Renal disease 3 (27.3%) 18 (4.0%) 0.011
Hepatic disease 1 (9.1%) 44 (9.8%) >0.999 (NS)
Pulmonary disease 1 (9.1%) 35 (7.8%) 0.597 (NS)
Brain disease 0 (0%) 45 (10.0%) 0.611 (NS)
Hypertension 6 (54.5%) 203 (45.3%) 0.763 (NS)
Diabetes mellitus 3 (27.3%) 72 (16.1%) 0.399 (NS)
Hyperlipidemia 1 (9.1%) 66 (14.7%) >0.999 (NS)
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procedure may be exposed as the volume of the local in-
jection solution decreases. With regard to age, Jang et al.
reported that the frequency of ESD-associated bleeding
(including intraoperative bleeding) was higher in patients
younger than 65 years of age as compared with that in pa-
tients who were 65 years of age or older [31]. This may be
attributable to the higher post-ESD physical activity as
compared to elderly patients undergoing the procedure,
and also the greater acid secretion in young people than
in the elderly. Patients with renal disease have delayed
wound healing as a result of tissue fragility, hypoprotei-
nema, and vascular disorders, as well as more marked ag-
gressive factors such as enhanced acid secretion and
increased gastrin levels, and reduced defense factors such
as prostaglandins, all of which may be expected to lead to
a delay in histological restoration of the ulcer and delayed
postoperative bleeding [5,32].In order to minimize the risk of postoperative bleeding,
we administer oral PPIs from the day before the operation
and use hemostatic treatment with hemostatic forceps or
a clip for exposed vessels at the base of the ulcer immedi-
ately after the procedure. In addition to ensuring these
measures, we believe that some additional measures
would be required in patients with large resected speci-
mens or lesions in the L segment and younger patients,
who were found in this study to be more prone to postop-
erative bleeding. For example, it is necessary to identify
blood vessels at the ulcer base after ESD, that are prone to
cause postoperative bleeding, using endoscopic Doppler
ultrasound or infrared imaging system [33,34], and to use
over-the-scope-clip for cerclage of the ESD ulcer and
medical adhesives for covering the ulcer [35,36]. As these
devices and drugs have been examined in only a small
number of patients, further study is desired. Second-look
endoscopy may be useful in patients who are prone to
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ESD, such as young patients and patients with renal
disease; therefore, further studies are required.
A limitation of this study was that it was a retrospect-
ive single-institution study. Furthermore, the number of
patients undergoing second-look endoscopy was lower
in the first half of the study period than in the second
half of the study period, which may have caused a bias.
Conclusion
In conclusion, performance of second-look endoscopy
within a few days after ESD did not reduce the incidence
of postoperative bleeding, and is hence considered to be
unnecessary. Postoperative bleeding was more likely to
occur within 24 hours of the ESD in patients with large le-
sions/resected specimens and lesions in the L segment,
and more likely to occur 24 hours or later in younger
patients and patients with concomitant renal disease.
However, the actual benefit of second-look endoscopy
must be elucidated in a prospective randomized controlled
trial in the future, and the risk factors for postoperative
bleeding identified in this study should be evaluated
further.
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